Clinically driven innovation has always been a fundamental driver for us at Senzime. Through innovation, product development and partnerships we keep strengthening our position on the market and enabling investments in our current product portfolio and development projects.
Senzime’s customer base mainly comprises university hospitals, as well as smaller-scale hospitals and clinics. Collaborations with partners and shared product development are central to our success, meaning we reach more patients, and thus reduce complications.
One of our strategic focuses is developing partnerships and collaborations with larger and smaller enterprises in the medical device sector.
- Connectivity license agreement with Masimo, a US-headquartered global leader in patient monitoring solutions
- Connectivity with Philips monitors, a major player in the field of hospital monitoring systems
- Partnership with Fukuda Denshi, our exclusive partner for rolling out TetraGraph technology in Japan
- Partnership with CoreSpiron, licensing partner for ExSpiron in China
Continuous development is vital for further improvements in patient safety and health, and all product development is in close partnership with customers. This is how we ensure that our products satisfy market needs.
An agile approach also enables us to adapt quickly to the market’s changing needs.
TetraGraph and ExSpiron are both based on clinical activities and well-founded research evidence. This is also the way we work to identify new innovations, close to clinical activities and research, and monitor trends in the clinical and technology spheres.
Insourcing our product manufacturing to our headquarters in Uppsala, Sweden, has enabled us to strengthen our partnerships between different corporate functions—a necessity for innovation, simultaneous with improving our capability for fast launches, and making products available on the market.
